Related Experiment Video
Updated: May 18, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Personalizing antiplatelet therapy with clopidogrel.
1Universitäts-Herzzentrum Freiburg-Bad Krozingen, Klinik für Kardiologie und Angiologie II, Bad Krozingen, Germany. dietmar.trenk@universitaets-herzzentrum.de
Clinical Pharmacology and Therapeutics
|September 6, 2012
Summary
Dual antiplatelet therapy with aspirin and clopidogrel is standard after coronary intervention. High on-clopidogrel platelet reactivity increases ischemic event risk, prompting strategies for personalized antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for preventing ischemic events post-percutaneous coronary intervention (PCI).
- Significant interindividual variability exists in patient response to clopidogrel, a key antiplatelet medication.
- Elevated on-clopidogrel platelet reactivity is linked to a higher risk of ischemic complications.
Purpose of the Study:
- To review factors influencing clopidogrel response variability.
- To discuss strategies for optimizing antiplatelet therapy effectiveness.
- To improve clinical outcomes in patients undergoing PCI and those with acute coronary syndromes (ACSs).
Main Methods:
- Literature review of clinical studies on clopidogrel therapy.
- Analysis of factors contributing to variable antiplatelet response.
- Discussion of platelet function testing and genotyping approaches.
Main Results:
- Identified clinical, demographic, and genetic factors affecting clopidogrel response.
- Demonstrated correlation between high on-clopidogrel platelet reactivity and increased ischemic risk.
- Highlighted potential for personalized medicine in antiplatelet therapy.
Conclusions:
- Tailoring antiplatelet therapy based on individual response can mitigate ischemic events.
- Platelet function testing and genotyping offer promising strategies for optimizing clopidogrel efficacy.
- Personalized antiplatelet strategies may improve clinical outcomes in high-risk cardiovascular patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...